09 December 2020: Database Analysis
Identification of a 6-Gene Signature Associated with Resistance to Tyrosine Kinase Inhibitors: Prognosis for Clear Cell Renal Cell Carcinoma
Qinke Li ABCE , Wenbo Yang CD , Maoqing Lu DF , Ronggui Zhang AG*DOI: 10.12659/MSM.927078
Med Sci Monit 2020; 26:e927078
Table 2 Survival rate and median survival time of patients with clear cell renal cell carcinoma in training cohort, validation cohort, entire cohort, and patients with metastatic disease (M1).
| Train cohort | ||
|---|---|---|
| High risk | Low risk | |
| 1-year survival rate | 87.2 (81.1–93.7) | 97.3 (94.2–100) |
| 3-year survival rate | 61.3 (52.2–71.9) | 88.6 (82.4–95.2) |
| 5-year survival rate | 44.0 (33.8–57.2) | 77.1 (67.2–88.4) |
| Median survival | 4.34 | Undefined |
| HR (high/low) | 3.70 (2.31–5.93) | |
| 1-year survival rate | 84.1 (77.4–91.3) | 97.3 (94.4–100) |
| 3-year survival rate | 65.6 (56.5–76.1) | 89.4 (83.4–95.9) |
| 5-year survival rate | 47.4 (37.1–61.4) | 73.0 (61.5–86.7) |
| Median survival | 5.24 | Undefined |
| HR (high/low) | 3.26 (2.01–5.29) | |
| 1-year survival rate | 86.1 (81.7–90.9) | 97.8 (95.9–99.7) |
| 3-year survival rate | 64.0 (57.4–71.2) | 89.7 (85.5–94.1) |
| 5-year survival rate | 47.1 (39.6–56.0) | 77.2 (70.2–84.9) |
| Median survival | 4.70 | Undefined |
| HR (high/low) | 3.48 (2.48–4.87) | |
| 1-year survival rate | 57.5 (44.9–73.5) | 82.5 (66.3–100) |
| 3-year survival rate | 27.2 (17.0–43.6) | 62.9 (43.0–91.9) |
| 5-year survival rate | 15.0 (7.3–30.5) | 47.1 (27.2–81.8) |
| Median survival | 1.51 | 4.55 |
| HR (high/low) | 3.10 (1.75–5.50) | |